In addition to its promising Parkinson’s trials, the company has also experienced success in schizophrenia . In December 2020, Cerevance released data from a Phase Ib biomarker study of CNV058, a drug that helps treat cognitive impairment associated with schizophrenia. Again, the company had used its NETSseq platform to create a drug that interacts with neurotransmitters to normalize MMN brainwaves, a common symptom of cognitive impairment in people diagnosed with schizophrenia.
2 Likes